Subcutaneous omalizumab + steroid may leads to higher number of participants achieving complete inhaled steroid withdrawal… compared with placebo + steroid (steroid reduction) (low certainty).
Subcutaneous omalizumab + steroid probably leads to higher >50% reduction in inhaled steroid usage 28 to 32 weeks compared with placebo + steroid (steroid reduction) (moderate certainty).
Subcutaneous omalizumab + steroid probably leads to lower number of participants with at least one exacerbation All asthmatic… compared with placebo + steroid (stable steroid) (moderate certainty).
Subcutaneous omalizumab + steroid probably leads to lower number of participants with at least one exacerbation Moderate to… compared with placebo + steroid (stable steroid) (moderate certainty).
Subcutaneous omalizumab + steroid showed no clear difference in number of participants with at least one exacerbation Severe asthma… compared with placebo + steroid (stable steroid) (low certainty).
Subcutaneous omalizumab + steroid showed no clear difference in mortality 16 to 60 weeks compared with placebo + steroid (stable steroid) (low certainty).
Subcutaneous omalizumab + steroid probably leads to lower hospitalisations 28 to 60 weeks compared with placebo + steroid (stable steroid) (moderate certainty).
Subcutaneous omalizumab + steroid probably leads to lower adverse event—serious 16 to 60 weeks compared with placebo + steroid (stable steroid) (moderate certainty).
Subcutaneous omalizumab + steroid probably leads to lower exacerbations requiring hospitalisation 28 weeks compared with placebo + steroid (steroid reduction) (moderate certainty).